Joint Pain Forum – News you can use!
17 European countries extend Celebrex arthritis drug label
(AFX) - Pfizer Inc said 17 European countries have agreed to extend the
Celebrex drug label to include symptomatic relief in the treatment of
ankylosing spondylitis in adults, a form of arthritis that affects the
Each of the 17 countries will now individually update the licence for
Celebrex to include the new labelling, following applicable local
The company said once each country updates
its labelling, Celebrex will be the first oral selective COX-2
inhibitor available in Europe to treat the condition. Ankylosing
spondylitis affects up to 0.9 pct of Europeans, Pfizer (nyse: PFE -
news - people ) said in a research update.
Map | CONTACT